1. Home
  2. MCRB vs DMRC Comparison

MCRB vs DMRC Comparison

Compare MCRB & DMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • DMRC
  • Stock Information
  • Founded
  • MCRB 2010
  • DMRC 2008
  • Country
  • MCRB United States
  • DMRC United States
  • Employees
  • MCRB N/A
  • DMRC N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • DMRC EDP Services
  • Sector
  • MCRB Health Care
  • DMRC Technology
  • Exchange
  • MCRB Nasdaq
  • DMRC Nasdaq
  • Market Cap
  • MCRB 165.3M
  • DMRC 187.8M
  • IPO Year
  • MCRB 2015
  • DMRC N/A
  • Fundamental
  • Price
  • MCRB $17.23
  • DMRC $10.44
  • Analyst Decision
  • MCRB Hold
  • DMRC Strong Buy
  • Analyst Count
  • MCRB 4
  • DMRC 1
  • Target Price
  • MCRB $73.67
  • DMRC $30.00
  • AVG Volume (30 Days)
  • MCRB 245.5K
  • DMRC 224.4K
  • Earning Date
  • MCRB 11-12-2025
  • DMRC 11-13-2025
  • Dividend Yield
  • MCRB N/A
  • DMRC N/A
  • EPS Growth
  • MCRB N/A
  • DMRC N/A
  • EPS
  • MCRB 10.22
  • DMRC N/A
  • Revenue
  • MCRB N/A
  • DMRC $35,479,000.00
  • Revenue This Year
  • MCRB N/A
  • DMRC N/A
  • Revenue Next Year
  • MCRB N/A
  • DMRC N/A
  • P/E Ratio
  • MCRB $1.68
  • DMRC N/A
  • Revenue Growth
  • MCRB N/A
  • DMRC N/A
  • 52 Week Low
  • MCRB $6.53
  • DMRC $7.77
  • 52 Week High
  • MCRB $24.67
  • DMRC $48.32
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 52.55
  • DMRC 60.32
  • Support Level
  • MCRB $17.00
  • DMRC $8.84
  • Resistance Level
  • MCRB $24.67
  • DMRC $9.62
  • Average True Range (ATR)
  • MCRB 1.79
  • DMRC 0.53
  • MACD
  • MCRB -1.40
  • DMRC 0.36
  • Stochastic Oscillator
  • MCRB 69.86
  • DMRC 93.47

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

Share on Social Networks: